162 related articles for article (PubMed ID: 27645692)
1. Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235.
Bazan JG; Duan F; Snyder BS; Horng D; Graves EE; Siegel BA; Machtay M; Loo BW
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):17-24. PubMed ID: 27645692
[TBL] [Abstract][Full Text] [Related]
2. Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235.
Markovina S; Duan F; Snyder BS; Siegel BA; Machtay M; Bradley JD
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):597-605. PubMed ID: 26461002
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
4. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.
Machtay M; Duan F; Siegel BA; Snyder BS; Gorelick JJ; Reddin JS; Munden R; Johnson DW; Wilf LH; DeNittis A; Sherwin N; Cho KH; Kim SK; Videtic G; Neumann DR; Komaki R; Macapinlac H; Bradley JD; Alavi A
J Clin Oncol; 2013 Oct; 31(30):3823-30. PubMed ID: 24043740
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.
Guberina M; Eberhardt W; Stuschke M; Gauler T; Aigner C; Schuler M; Stamatis G; Theegarten D; Jentzen W; Herrmann K; Pöttgen C
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1439-1447. PubMed ID: 30710323
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235.
Ohri N; Duan F; Machtay M; Gorelick JJ; Snyder BS; Alavi A; Siegel BA; Johnson DW; Bradley JD; DeNittis A; Werner-Wasik M
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25688115
[TBL] [Abstract][Full Text] [Related]
7. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
[TBL] [Abstract][Full Text] [Related]
8. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment 18F-FDG PET Textural Features in Locally Advanced Non-Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235.
Ohri N; Duan F; Snyder BS; Wei B; Machtay M; Alavi A; Siegel BA; Johnson DW; Bradley JD; DeNittis A; Werner-Wasik M; El Naqa I
J Nucl Med; 2016 Jun; 57(6):842-8. PubMed ID: 26912429
[TBL] [Abstract][Full Text] [Related]
10. Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in Patients with Adrenocortical Carcinoma.
Satoh K; Patel D; Dieckmann W; Nilubol N; Kebebew E
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S714-20. PubMed ID: 26282908
[TBL] [Abstract][Full Text] [Related]
11. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
12. Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.
Roengvoraphoj O; Wijaya C; Eze C; Li M; Dantes M; Taugner J; Tufman A; Huber RM; Belka C; Manapov F
Strahlenther Onkol; 2018 Feb; 194(2):107-115. PubMed ID: 29116336
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
Liao S; Penney BC; Zhang H; Suzuki K; Pu Y
Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
15. Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer.
Lee P; Bazan JG; Lavori PW; Weerasuriya DK; Quon A; Le QT; Wakelee HA; Graves EE; Loo BW
Clin Lung Cancer; 2012 Jan; 13(1):52-58. PubMed ID: 21703935
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of post-induction chemotherapy 18F-FDG PET-CT in stage II/III non-small cell lung cancer before (chemo-) radiation.
Ganem J; Thureau S; Gouel P; Dubray B; Salaun M; Texte E; Vera P
PLoS One; 2019; 14(10):e0222885. PubMed ID: 31603916
[TBL] [Abstract][Full Text] [Related]
17. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
[TBL] [Abstract][Full Text] [Related]
18. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
[TBL] [Abstract][Full Text] [Related]
19. Standard uptake value and metabolic tumor volume of ¹⁸F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer.
Huang W; Zhou T; Ma L; Sun H; Gong H; Wang J; Yu J; Li B
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1628-35. PubMed ID: 21617977
[TBL] [Abstract][Full Text] [Related]
20. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]